We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Placebo Trials Risky for Asthmatic Children

By HospiMedica staff writers
Posted on 19 Jan 2004
Involving asthmatic children in the placebo arm of a clinical trial can be harmful and is ethically unjustified, according to a study published in the January 2004 issue of Pediatrics.

Researchers made a systematic review of all clinical trials involving asthmatic children between 1998 and 2001. More...
They found that children with asthma were more than twice as likely to be forced to withdraw because of asthma exacerbation if they did not receive standard asthma therapy, compared to children who received standard treatment. Out of 70 published studies, 45 compared a drug against a placebo and all involved subjects under 18, while 14 studies involved only children. Although 22 studies required all subjects to begin or continue their medications, 48 of the studies did not. In only 18 studies, subjects with more than mild asthma were taking anti-inflammatory medications prior to the study.

"These children have been exposed to unnecessary risks and harm because the very medication they depend on is being withheld from them during these studies,” noted Lainie Briedman Ross, M.D., Ph.D., associate professor of pediatrics at the University of Chicago (IL, USA; www.uchicago.edu), who led the study. "It's unconscionable that children are not properly treated when joining these studies. Those who don't get the experimental drug should get standard treatment.”

Moreover, said the researchers, many of the studies were not groundbreaking, were testing therapies similar to what was already available, and nearly all were funded by pharmaceutical companies.



Related Links:
U. of Chicago

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.